Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder and is associated with symptoms of heart failure and increased risk of sudden cardiac death. The most common condition is obstruction of the left ventricular outflow tract. Surgical septal myectomy and alcohol septal ablation are the 2 accepted modes of septal reduction therapy and are indicated when there are advanced symptoms and a peak left ventricular outflow gradient > _50 mmHg. Advantages of alcohol septal ablation are limited groin approach, reduction of obstruction of the left ventricular outflow tract and functional improvement, but there are higher chances for intracardiac device implantation and residual obstruction. Septal myectomy offers very low mortality, absolute and immediate resolution of obstruction of the left ventricular outflow tract and survival comparative to a matched general population with almost negligible residual obstruction. It is recommended that patients with obstructive hypertrophic cardiomyopathy should be treated at experienced centres.
INTRODUCTION
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Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disorder affecting 1 in 500 people within the general population and is associated with symptoms of heart failure and an increased risk of sudden cardiac death (SCD) [1] . According to the European and American guidelines, HCM is defined as asymmetric or disproportionate left ventricular hypertrophy in the absence of any other cardiac or systemic disease [2, 3] .
To date, more than 1500 gene mutations are related to the clinical expression of HCM [4] . Genetic testing is mostly used for family screening and confirmation of phenocopies but has no or only minor impact on the clinical management of the disease.
The disease presents with different morphologies and pathophysiological conditions with non-obstructive and obstructive forms. Obstruction can be observed at different levels (midventricular and left ventricular outflow tract). The most common is obstruction of the left ventricular outflow tract (LVOTO) present in about 50-75% of patients. Most cases respond well to medical management [beta-blockers, calcium channel blockers (verapamil-type) and disopyramide]. Some patients remain symptomatic despite maximal medical therapy and maintain peak gradients > _50 mmHg and New York Heart Association (NYHA) functional class III/IV. These patients are candidates for septal reduction therapies (SRTs) including surgical septal myectomy (SM) and alcohol septal ablation (ASA). Surgery for obstructive HCM (HOCM) was introduced by Morrow in 1961 [5] and continues to be the gold standard for the treatment of HOCM. The classic approach is a transaortic resection of septal hypertrophy. A few centres organized programmes for SM in patients with apical and midventricular hypertrophy and consecutively reduced stroke volumes to increase the size of the left ventricular cavity and cardiac output [6] . Although SM has been well adopted in North America, Europe has popularized ASA, which was introduced in 1994 by Sigwart, as the transcatheter approach to reduce septal hypertrophy [7] . Both techniques have been refined and improved over the past decades, mostly benefitting from echocardiographic guidance, that has become the standard of practice.
The concept of ASA with reduction of surgical trauma is intriguing and has led to many discussions regarding the best invasive treatment option to achieve substantial septal reduction including success of intervention, complications, survival and patient selection. Still there are gaps in knowledge, and because there are no randomized trials, evidence is based on the results of high-volume centres performing SM [8, 9] and ASA [10] . This has also become a matter of debate between North America and Europe [11] . There are many differences in practice around the world as noticed when cohort studies, registries and practice guidelines are reviewed.
The results of surgery for HOCM are well established [8, 9] . Neither ASA nor surgery for HOCM are boutique procedures and address a complex and still misunderstood disease. The approaches must be balanced not looking for discounts but for the best treatment option for every individual [12] . Current opinion is that patients with HOCM should be managed at experienced centres to provide best medical care.
The debate is then served. The therapeutic approaches, their rationale and results will be discussed. Renowned experts in the field guarantee objectivity and appropriate contrast of opinions.
ALCOHOL MYOCARDIAL SEPTAL ABLATION AND OTHER NON-SURGICAL APPROACHES
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To date, there are no randomized data on clinical outcomes after non-surgical therapies in patients with HOCM who remain symptomatic despite optimal medical treatment. Nevertheless, ASA introduced by Sigwart [7] represents the most prevalent alternative percutaneous technique to SM. Injection of a small amount of desiccated alcohol into the dedicated septal perforator artery resulted in basal septal necrosis compatible with colliquative necrosis and subsequent shrinkage of the myocardial tissue ( Fig. 1) , leading to decrease in obstruction. Although encouraging results of smaller registries have been published [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , longterm safety and efficacy of ASA have been controversially debated [11, 23, 24] . Recent data from the Euro-ASA registry, the largest multinational registry of this kind, demonstrated favourable periprocedural [25] and long-term results for highly [26] and mildly symptomatic [27] patients. This refers to heart failure (NYHA class III/IV) and angina, in patients refractory or intolerant to medical therapy presenting with LVOT pressure peak gradient > _50 mmHg.
Mean alcohol doses of 2.2 ± 0.9 ml given in highly symptomatic patients and of 2.0 ± 1.1 ml in mildly symptomatic ones resulted in 30-day mortality rates of 1.0% and 0.6%, respectively. Post-ASA all-cause mortality was 2.42 (95% confidence interval 2.07-2.82) deaths per 100 patient-years in highly symptomatic patients. None of the 160 mildly symptomatic patients who survived the first 30 days was lost during the median follow-up of 4.8 years [26, 27] . Independent predictors of all-cause mortality were higher age, end-diastolic septum thickness, NYHA class and LVOT pressure gradient before ASA [26] . Outcomes similar to SM not just in terms of mortality but also gradient reduction, improvement of symptoms and exercise capacity have been repeatedly demonstrated [7, 20, [28] [29] [30] [31] [32] . Improvement in functional capacity of one or more NYHA classes can be expected in about 86% of patients after ASA. The majority of the non-responders may still be candidates for re-ASA or SM [26] . However, the incidence of re-SRT is higher after ASA compared with SM [31] .
The European Society of Cardiology (ESC) 2014 Guidelines [2] provide Class I, Level of Evidence B recommendation for any kind of SRT to improve symptoms in NYHA Class III-IV patients with a resting or maximum provoked LVOT pressure gradient of > _50 mmHg, despite maximum tolerated medical therapy. There is preference neither for SM nor for ASA. If recurrent exertional syncope is considered as HOCM patients' chief complaint, the recommendation for SRT including ASA is Class IIa, Level of Evidence C. ASA has not been recommended yet in mildly symptomatic patients. The 2011 American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) guidelines discouraged ASA in adults <40 years of age if SM was a viable option [3] . American guidelines favour SM over ASA for the majority of the eligible patients with HOCM presenting with severe drug-refractory symptoms (Class IIa, Level of Evidence B recommendation).
Favourable short-and long-term results, as recently published, can just be achieved by strict adherence to established standards for ASA as follows [2, 4, 26, 27 ]:
• Assessment of potential candidates for ASA by experienced multidisciplinary teams and decision making by institutional heart teams are mandatory prior to intervention.
• Other anatomical findings such as relevant papillary muscle and mitral valve abnormalities, in particular, degenerative mitral valve disease and any mitral regurgitation (MR) not caused by systolic anterior leaflet motion (SAM phenomenon) but requiring surgical treatment should be excluded from ASA.
• ASA is considered slightly less effective and therefore might be avoided in patients with extensive septal scarring on cardiac magnetic resonance imaging and in patients with excessive septal hypertrophy (end-diastolic thickness of the interventricular septum > _25 mm).
• ASA should not be favoured in patients with just mild-tomoderate septal hypertrophy (end-diastolic thickness of the interventricular septum < _16 mm), because there is a higher risk of incidental ventricular septal defect (VSD).
• ASA should be indicated restrainedly in children, adolescents and young adults because long-term data on the late effects of a myocardial scar are not available for these groups. In addition, technical difficulties and potential hazards of the procedure in smaller children and infants are comparatively greater.
• Guidance of ASA by myocardial contrast echocardiography is essential. Myocardial contrast must be exclusively localized in the basal interventricular septum.
• Alcohol application should not be started until potential reflux of alcohol beneath the inflated balloon into a coronary main branch is excluded by the application of radio contrast through the balloon catheter.
• In the majority of the cases, an intracoronary alcohol volume of 2.0 ml or even less is effective. Higher doses of alcohol are slightly more effective in reducing LVOTO but may result in a higher incidence of periprocedural complete heart block and other complications. Since the post-procedural LVOTO is otherwise independently associated with worse functional status and prognosis, the choice of optimal therapies should focus on the elimination of LVOTO. Nevertheless, alcohol volumes exceeding 3.0 ml should be administrated with caution.
• Haemodynamic efficacy should be continuously monitored by reading instantaneous pressure gradients. The use of double-lumen pigtail catheter is recommended.
• Application of alcohol should be performed in increments of 0.2-0.3 ml as tolerated by the patient.
• Prophylactic pain management and insertion of a temporary pacemaker lead are highly recommended prior to the start of the intervention.
• Non-alcohol septal embolization techniques are not recommended due to lack of data.
The Euro-ASA registry confirmed complete heart block to be the main non-fatal complication. It occurs temporarily in about 25% and permanently requiring pacemaker implantation (PMI) in another 12% of a classical patient population until 30 days after ASA [26] . Below this level, ASA usually provokes right bundle branch block, whereas SM is more frequently associated with left bundle branch block [33] . However, the PMI rate obviously depends on the amount of alcohol used [26] but seems to be generally associated with a higher incidence compared with SM. The same has been described for intracardiac defibrillator (ICD) implantation rates, which may be required up to 5 times higher in SM patients than in ASA patients [31, 32] , although Euro-ASA registry has found sustained ventricular tachycardia or fibrillation requiring electrical cardioversion to occur in about 1.3% of patients [26] . This is lower than that previously reported by a smaller study [34] .
ICD and PMI are not only complementary after ASA but also represent stand-alone non-surgical therapies in symptomatic HOCM. However, the benefits of dual-chamber cardiac pacing seem to be based on pathophysiological measures rather than on clinically relevant end-points [35] . That is why current ESC guidelines on the diagnosis and management of HOCM provide with Class IIb, Level of Evidence C recommendation for standalone therapy [2] , in line with 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy, suggesting PMI in adult patients who are unwilling to undergo other SRTs or who have other pacing indications, with the good sense of programming a dynamic paced atrioventricular interval to obtain full right ventricular capture also during exercise [36] . ICD implantation is certainly indicated in patients with HOCM who have experienced resuscitated cardiac arrest. In contrast, primary prevention entails difficult decision-making. According to the current guidelines, the HOCM risk SCD model categorizes patients to be on high, intermediate and low risk [2] . This model considers not just widely used risk factors associated with SCD (i.e. family history of SCD, unexplained syncope, maximum left ventricular wall thickness and non-sustained ventricular tachycardia episodes) but also includes prognosticators such as left atrial diameter, LVOT gradient, age and general health of the patient. Generally, ICD implantation is definitively indicated if the estimated 5-year risk calculated by this model is > _6% [2] . Nevertheless, the model seems to have some weak points that have to be taken into account:
• The risk of SCD is underestimated in cases with extreme hypertrophy (maximum left ventricular wall thickness > _35 mm), because the relation between left ventricular hypertrophy and SCD is not linear. • The risk model is not applicable to metabolic or infiltrative diseases and genetic syndromes.
• The model does not help to predict the risk of SCD in patients undergoing any kind of SRT.
Indeed, data regarding patients post-SRT are ambiguous [26, 34, 37] , considering that some patients undergoing any SRT fall in the high-risk category and, therefore, may have already been implanted with ICD before the procedure. Inconsistency in data could also be triggered by procedural modifications in SRTs. Even if from an arrhythmic standpoint, the scar created in the septum by SM and ASA could be potentially arrhythmogenic and, therefore, could pre-empt the mortality benefits deriving from the elimination of obstruction, which is not clear.
SEPTAL MYECTOMY-SURGICAL PERSPECTIVE FOR A GREAT DEBATE
Eduard Quintana, Barcelona, Spain; Joseph E. Dearani, Rochester, MN, USA SM has effectively served patients with HOCM worldwide for 5 decades. It is regarded in North America as the first SRT for symptomatic and medically refractory LVOTO [3] . In Europe, there has been a continuous and worrisome decrease in the expertise and number of SM for HOCM. This continued decline of patient referral to SM has been in favour of ASA. This paradigmatic switch in SRT in Europe has not been accompanied by a robust outcome data analysis [11] .
Contrary to the widespread misconceptions regarding surgery for HOCM, SM is an extremely safe and effective operation. Recent data from large referral centres point at a safety profile of SM similar to or better than what is currently expected for mitral valve repair for degenerative disease [9] .
Classically, the indications for any SRT have been severe symptoms (shortness of breath, dyspnoea, angina and syncope) and severe LVOTO (peak gradient > _50 mmHg) under appropriate medical therapy or intolerance to medication. The low operative mortality and morbidity associated with SM has justified earlier indication for surgery to less symptomatic populations (NYHA Class II) if significant basal obstruction is demonstrated [38] . In addition, SM is also justified in the presence of concomitant cardiac abnormalities (e.g. aortic valve disease, coronary disease, atrial fibrillation).
Currently, the literature and guidelines focus on treatment strategies to decrease or abolish LVOTO (basal obstruction) with different degrees of associated MR due to SAM of the mitral valve. Importantly, obstruction at the basal level and secondary MR are 'dynamic' and can vary widely between examinations based on preload and afterload conditions and heart rate. Negative inotropic medications, such as beta-blockers and calcium channel blockers, have an impact on the measured obstruction. A perfect SM should lead to resolution of obstruction and SAM-mediated MR, at rest and under exercise conditions. This should be achieved without drug therapy.
HOCM expresses in a myriad of unique phenotypes. Thus, LVOT and ventricular anatomy is seldom the same. Significant septal hypertrophy can be localized at the base of the heart or the midventricular level. In addition to septal morphology, it is not uncommon that the presence of anomalous chordae or muscle attachments between the mitral apparatus/papillary muscle and the ventricular septum or posterolateral free wall can further contribute to obstruction. During SM, the operating surgeon has the ability to tailor the operation to ensure enough resection of the muscle and division of abnormal attachments to abolish residual dynamic or fixed obstruction. The effect of ASA can be limited by coronary anatomy, the presence of abnormal mitral valve attachments, the distribution of septal hypertrophy and behaviour of ethanol at the tissue level. SM is not limited from such restrictions and is the preferred approach to invasively treat more advanced disease and in concert with these additional abnormalities. The importance of comprehensive imaging to identify septal anatomy and these potential abnormalities cannot be overemphasized. For such reasons, in the absence of a randomized trial, this unbalanced referral treatment can compromise any comparison of outcomes (arising from registries or observational studies) between both techniques.
The excellent early and late outcomes associated with SM continue to be achieved by means of median sternotomy, cardiopulmonary bypass and cardioplegic arrest. In general, an appropriate SM includes extension of the muscular resection to the midventricular level. This predictably abolishes the gradients and eliminates SAM-mediated MR. Adjunctive mitral valve procedures should be reserved for structural abnormalities. In general, when SAM is present, a transaortic resection with an extension to the midventricular level (i.e. resection down to and opposite the papillary muscles) is sufficient and effective at abolishing the gradient and eliminating MR. In some circumstances, midventricular obstruction may also need to be approached via left apical ventriculotomy because of difficult exposure, regardless of the size of the aortic annulus. There are no long-term data available that prove the superiority of other approaches such as transmitral SM to the conventional extremely successful approach.
It has been suggested that SM candidacy decreases with increasing age. The limits of operability are arbitrary, and most patients beyond the age of 70 continue to benefit greatly with surgery. Would we not offer mitral valve repair for flail posterior leaflet to a septuagenarian? Or a combined valve coronary operation at the age of 75? While relative older age (i.e. >70 years) requires a closer preoperative evaluation to delineate other comorbid conditions, the fact is that the majority are still good candidates for surgery that can be performed with low risk. Consequently, we have not used age as a trigger to choose between SM and ASA. Surgery for older patients can sometimes be more beneficial due to higher incidence of associated coronary disease, arrhythmia or valve problems that can be addressed concomitantly and still with very low risk (Videos 1-3).
Very early outcomes with SM (within 30 days) are excellent, and the risk of perioperative death, malignant ventricular arrhythmias, stroke, valve injury or ventricular septal defect is <1% in experienced centres [39] [40] [41] . In the absence of preoperative right bundle branch block or a previous ASA, the incidence of complete atrioventricular block is approximately 2%. Early extubation can be accomplished in the majority of the patients following SM, and the length of hospital stay is 4-5 days in the absence of other comorbidities. Return to unrestricted physical activity is judged on an individual basis and on average takes 6-8 weeks.
We have to pay tribute to old SM series available in the literature. Twenty years ago, Schonbeck et al. [42] reported a 72% 15-year survival for patients operated between 1965 and 1995. It is important to point that 20% of those patients received concomitant procedures (coronary surgery, valve surgery, etc.) with its potential impact on long-term events. In a more recent report Video 1: Parasternal long-axis view; a 72-year-old woman with HOCM and invalidating symptoms. There are degenerative changes in both mitral and aortic valves. Such changes may be related to long-standing abnormal flow patterns secondary to left ventricular outflow tract and posteriorly directed mitral regurgitation jet. She underwent septal myectomy and a maze IV operation for concomitant permanent atrial fibrillation. Age is not a contraindication for surgical septal reduction therapy.
analysing 6 different series, survival beyond 10 years was well above 80% (including concomitant procedures from 21-43%) with about 90% of patients in NYHA Class I-II at follow-up [43] . The variety of concomitant procedures included in such series constitutes a significant limitation to compare these outcomes to those achieved by isolated ASA. Since the publication of these initial reports, significant improvements have been made in myocardial protection, perioperative care, preventive ICD implantations and medical therapy. Then, for isolated SM without concomitant cardiac diseases, one would expect even better outcomes. Freedom for HCM-related mortality after SM at 10 years is 95% [41] .
Our cardiology community has raised concerns about increased sudden death and arrhythmia risk following ASA [44, 45] . This continues to justify many ICD implants worldwide. In contrast, there are no reports that point at an increased arrhythmogenicity after SM, and, in fact, there are reports suggesting a decreased risk of ventricular arrhythmias [46] . The abolishment of obstruction with SM (even after provocation) may explain why survival after SM approximates that of an age-matched population and a drastic decrease in appropriate ICD shocks [47] .
Proper patient advice regarding the need for ASA or SM repeated procedures is mandatory before any SRT choice is made. The proportion of patients requiring a redo SM is around 1%. When repeat SM is required, it is more often due to an inadequate initial SM as opposed to regrowth of the muscle. This likely reflects surgical inexperience early in individual SM experience. Recently published registries acknowledge the need for repeat SRT after ASA ranging from 10% to 15% within the first 10 years after the procedure (some patients undergoing more than 2 ablations) [13, 26] . Residual obstruction (> _30 mmHg) after ASA has a direct relationship with increased cardiovascular mortality [48] . Rescue SM after ASA carries an increased risk of complete heart block (>30%) and early outcomes of surgery may be compromised by prior ASA [49] .
The presence of either an ICD or a pacemaker may carry substantial risk as is present in non-HOCM patients implanted with intracardiac devices [50] . A newly implanted ICD affects professional life and leisure time activities, forcing patients to adapt to this new situation and accept limitations over time [51] . The rate of inappropriate discharges is unacceptably high (27% of patients experiencing > _1 shocks) [52] . Other issues such as secondary tricuspid regurgitation, endocarditis and device-related nuances are typically under-reported [53] . This should constitute another consideration when choosing the best form of SRT.
Exercise tolerance after SRT has been assessed in some studies with a trend in better functional capacity after SM [54] . Limitations for a true comparison of this important outcome remain. Firoozi et al. [55] objectively compared the gain in oxygen consumption after both SRT, concluding a clear superiority after SM.
There is scanty information with regard to the economics of SRT in the short-and long term. Clear differences in the need for repeat procedures and the need for device implantation have to be challenged against the inherent physical recovery time required after SM. This will need further investigation.
It has been demonstrated that excellent SM outcomes may only be achieved in experienced centres under the care of an expert multidisciplinary team of physicians. SM continues to be the gold standard for SRT for patients with symptomatic HOCM. In experienced centres, early mortality is <1% with a predictable resolution of obstruction that is long-lasting, an improved quality of life with a low probability of need for reoperation and no added risk of arrhythmia or dependency on implantable devices (Table 1 ). This 'cut that heals' is the benchmark to which any other SRT options for HOCM should be compared. She experienced complete resolution of heart failure symptoms, restoration of sinus rhythm and leads a normal lifestyle 2 years after surgery.
DISCUSSION
Carlos A. Mestres, Christiane Gruner, Zürich, Switzerland HOCM continues to be a poorly understood disease, despite intensive and extensive investigations over the past couple of decades. Current information suggests that this is essentially a surgical disease, and outcomes with surgical treatment are excellent based on long periods of follow-up compared with ASA cohorts [42] . This applies to early mortality, reduction/elimination of LVOT gradient, pacing requirements and long-term survival [9, 56, 57] . As ASA has become a well-acknowledged alternative in selected groups of patients, information is also available regarding early outcomes and follow-up data [13, 15, 58] . A quick overview of the literature confirms that there is no information derived from well-designed, randomized and appropriately powered comparative studies. Patient selection in high-volume North American HOCM referral centres clearly favours surgery because of such excellent outcomes that render comparisons to ASA less relevant. This is a major issue in the era of evidence-based medicine. The reader might get confused at the time of analysing studies from individual centres, most of them producing data from small retrospective cohorts.
The previous sections produce what can be considered controversial or complementary information. Studies supporting ASA focus on the reduction of the LVOT gradient and improvement of symptoms that may by similar than in SM patients [18-20, 59, 60] . Some cases studies may be skewed by over supporting the approach as that of Liebregts et al. [60] , in which a surprising definition of the elderly and the young based on a difficult-to-accept cut-off age value for the westernized patients is introduced. Despite the good results from ASA studies, there are limitations and concerns, namely a necessary optimal patient selection ( Table 1) for ASA and the very high requirements for pacing, periprocedural and over time, together with the need for a repeated ASA or SM. This is well acknowledged in single-centre studies, registries and meta-analyses [22, 26, 31, 32, 58] and has been summarized in the cardiology section of this debate. Intracardiac device use may be in excess of 10%, which certainly is higher than after SM and is categorized as 'frequent' [58] . Furthermore, the discussion on dysfunctions of implantable devices [51, 61] needs also careful analysis not to overestimate their potential benefits, as device implantation per se is not benign.
With regard to SM, data are clear in terms of early and late outcomes [11, 56, 57, 62, 63] that extend well into the third decade of follow-up [42] . It is agreed that SM is the optimal therapy when drug therapy fails in symptomatic patients, although it seems that patient assignment for therapy based only on symptoms might be controversial [64] . However, we want to stress that the indication for SRT also has to take into account the capabilities of the treating centre, because the outcome of high-volume HCM centres cannot be transferred anywhere. We suggest that patients should be transferred to high-volume centres whenever possible, and if this is not the case, we strongly recommend not to perform any SRT procedure in almost asymptomatic patients. SM addresses populations that cannot be managed with ASA as those with abnormalities of the mitral valve and subvalvular apparatus including anomalies of papillary muscles, septal attachments or excessive hypertrophy, as defined in Table 1 , and accessory muscle bundles [57, 62, 63] . Table 2 is self-explanatory, as it summarizes the differences between approaches in complications and outcomes. Major advantages of ASA include limited groin approach, LVOTO and functional improvement but higher chances for intracardiac device implantation and residual obstruction. SM offers very low mortality, absolute and immediate resolution of LVOTO and survival comparative to a matched general population with almost negligible residual obstruction. All this is considered in practice guidelines, thus supporting SM [3, 4] as the preferable option, although this is still not contemplated in the European guidelines [2] . However, it might not be easy to get rid of strong controversy [65, 66] for the time being.
CONCLUSIONS
SM remains the gold standard in the treatment of HOCM. ASA emerged over 20 years ago as an alternative therapy to surgery. Outcomes are related to patient selection and strict observance of ASA standards. We recommend a multidisciplinary approach and careful patient selection to either one of the septal reduction procedures, which is key. If possible, they should be performed at experienced centres. To achieve better insights into outcome data and improve patient care as an ultimate goal, the implementation of an international registry for SRT would be very helpful.
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